膜性肾病：何去何从？ - Suppr

Membranous nephropathy: quo vadis?

作者信息

Cattran Daniel C

出版信息

Kidney Int. 2002 Jan;61(1):349-50. doi: 10.1046/j.1523-1755.2002.00125.x.

DOI:10.1046/j.1523-1755.2002.00125.x

PMID:11786118

Abstract

摘要

相似文献

Membranous nephropathy: quo vadis?

Kidney Int. 2002 Jan;61(1):349-50. doi: 10.1046/j.1523-1755.2002.00125.x.

Future perspectives in membranous nephropathy.

Nephrol Dial Transplant. 1992;7 Suppl 1:119-21.

Molecular pathogenesis of membranous nephropathy.

Kidney Int. 1992 Apr;41(4):1090-105. doi: 10.1038/ki.1992.166.

What do we know about lupus membranous nephropathy? An analytic review.

Arthritis Rheum. 2002 Aug;47(4):450-5. doi: 10.1002/art.10417.

Predicting progression in membranous glomerulonephritis.

Nephrol Dial Transplant. 1992;7 Suppl 1:48-52.

[A case of anti-GBM glomerulonephritis and membranous nephropathy in a patient with primary biliary cirrhosis].

Nihon Jinzo Gakkai Shi. 2012;54(4):550-5.

Rituximab in membranous nephropathy after haematopoietic stem cell transplantation.

Nephrol Dial Transplant. 2008 Aug;23(8):2700-1; author reply 2701. doi: 10.1093/ndt/gfn110. Epub 2008 Apr 2.

[Membranous nephropathy. Preface].

Nihon Jinzo Gakkai Shi. 2011;53(5):667.

Early prediction of treatment outcome in idiopathic membranous nephropathy.

QJM. 1995 Dec;88(12):889-94.

Membranous nephropathy due to malignancy: Is end stage kidney disease an irreversible final route?

Clin Nephrol. 2024 May;101(5):260-261. doi: 10.5414/CN111326.

引用本文的文献

A multicenter retrospective study on comparing the efficacy and safety of the therapy of intermittent cyclophosphamide and corticosteroids versus rituximab for primary membranous nephropathy.

Ren Fail. 2024 Dec;46(2):2409353. doi: 10.1080/0886022X.2024.2409353. Epub 2024 Oct 1.

Efficacy and safety of Mahuang Fuzi and Shenzhuo Decoction for treatment of primary membranous nephropathy: a multicenter prospective trial.

Ren Fail. 2024 Dec;46(1):2320834. doi: 10.1080/0886022X.2024.2320834. Epub 2024 Mar 14.

Primary membranous nephropathy: an endless story.

J Nephrol. 2023 Mar;36(2):563-574. doi: 10.1007/s40620-022-01461-3. Epub 2022 Oct 17.

Depletion of B lymphocytes in idiopathic membranous glomerulopathy: results from patients with extended follow-up.

Nephron Extra. 2013 Jan;3(1):1-11. doi: 10.1159/000345487. Epub 2013 Jan 5.

Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.

Nephrol Dial Transplant. 2013 Jan;28(1):137-46. doi: 10.1093/ndt/gfs379. Epub 2012 Sep 17.

Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy.

Clin J Am Soc Nephrol. 2011 Dec;6(12):2846-53. doi: 10.2215/CJN.04020411.

[Membranous glomerulonephritis].

Internist (Berl). 2003 Sep;44(9):1120-30. doi: 10.1007/s00108-003-1022-5.

[Treatment of glomerulonephritis].

Internist (Berl). 2003 Sep;44(9):1083-9. doi: 10.1007/s00108-003-1029-y.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Membranous nephropathy: quo vadis?

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献